Arcutis Biotherapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARQT Nasdaq 2830 www.arcutis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics (ARQT) Showcased Fresh ZORYVE Data, Is It Still 28% Below Fair Value? - Oct 9th, 2026 11:14 pm
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical - Oct 9th, 2026 6:00 am
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award - Oct 6th, 2026 6:19 am
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 2nd, 2026 2:00 pm
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Oct 1st, 2026 6:55 am
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options - Sep 29th, 2026 7:15 am
AXT Inc. (AXTI) Climbs 16% on S&P 600 Addition - Sep 21st, 2026 2:00 pm
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength? - Sep 21st, 2026 5:33 am
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study - Sep 17th, 2026 8:48 am
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last? - Sep 17th, 2026 8:38 am
Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11% - Sep 17th, 2026 1:20 am
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 - Sep 4th, 2026 5:15 pm
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - Sep 2nd, 2026 2:00 pm
Here's Why You Should Add ARQT Stock to Your Portfolio Now - Aug 28th, 2026 8:58 am
Arcutis Biotherapeutics (ARQT) Faces A Valuation Test, Is It Still A Bargain? - Aug 27th, 2026 7:07 pm
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Aug 27th, 2026 2:27 am
5 Biotech Stocks Worth Adding to Your Portfolio Now - Aug 26th, 2026 8:19 am
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer - Aug 24th, 2026 2:01 pm
Arcutis (ARQT) Q2 2026 Earnings Call Transcript - Aug 12th, 2026 3:28 pm